Tonghua Dongbao: No more than RMB 360 million of shares planned for repurchase and cancellation

On the evening of March 9, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") announced its plan to buy back no fewer than 12 million and no more than 240 million shares with its own funds through centralized bidding transactions, accounting for 0.60% to 1.19% of the Company's total share capital. The repurchase is expected to last 6 months from the date when the repurchase plan is approved at the shareholders meeting. As planned, the unit price of the repurchased shares will not exceed RMB 15, and the total repurchase amount will be no more than RMB 360 million.

Tonghua Dongbao: First subject enrolled in phase I clinical trial of the world's first triple-target inhibitor (SGLT1/ SGLT2/ DPP4)

Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") has initiated the phase I clinical trial of its triple-target inhibitor (THDBH101 Tablets/WXSHC071 Tablets) in China, after receiving the notice of approval from the National Medical Products Administration (NMPA). Recently, the first subject has been successfully enrolled.

Hospital-company cooperation: Tonghua Dongbao partners with the Second Xiangya Hospital of Central South University

On February 22, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") signed a strategic cooperation agreement and the first cooperative technology development agreement with the Second Xiangya Hospital of Central South University. The signing ceremony is also the unveiling ceremony for the strategic cooperation base of the two parties.

Tonghua Dongbao announces NMPA acceptance of registration application for empagliflozin

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a notification of acceptance from the National Medical Products Administration (NMPA) on the registration application for empagliflozin.

Tonghua Dongbao 2021 milestones—value-driven innovation and R&D

2021 was a bumper year for Tonghua Dongbao's innovation and transformation. The Company is fast-tracking its biomedical innovation by fully focusing on the R&D of novel drugs, expanding R&D pipelines, and improving R&D efficiency. It is also extending its reach to the treatments of endocrine diseases other than diabetes. At the same time, the Company is striving to build a high-quality, innovative R&D team, which now consists of about 400 professionals with a doctorate or master's degree.

Tonghua Dongbao announces NMPA acceptance of registration application for empagliflozin DS

Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a notification of acceptance from the National Medical Products Administration (NMPA) on the registration application for empagliflozin drug substance (DS).